Compare Stocks: CLLS, JBIO, WVE, and LXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$3.18 +8.2%	$2.93	$2.35 ▼ $5.48	$295M	2.91	17,862 shs	10,053 shs
JBIO Jade Biosciences	$23.81 +2.6%	$20.07	$6.67 ▼ $28.00	$1.48B	1.49	813,344 shs	1.09 million shs
LXRX Lexicon Pharmaceuticals	$2.34 -0.4%	$2.24	$1.03 ▼ $2.68	$1.05B	1.08	2.91 million shs	2.31 million shs
WVE WAVE Life Sciences	$5.20 -0.8%	$5.88	$5.01 ▼ $21.73	$1.03B	-1.26	2.76 million shs	6.05 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	+8.16%	+18.22%	+10.42%	-18.88%	+13.98%
JBIO Jade Biosciences	+2.59%	+7.06%	+11.57%	+1.97%	+224.83%
LXRX Lexicon Pharmaceuticals	-0.43%	-0.85%	+10.38%	+4.93%	+110.81%
WVE WAVE Life Sciences	-0.76%	-13.62%	-15.17%	-23.19%	-40.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$3.18 +8.2%	$2.93	$2.35 ▼ $5.48	$295M	2.91	17,862 shs	10,053 shs
JBIO Jade Biosciences	$23.81 +2.6%	$20.07	$6.67 ▼ $28.00	$1.48B	1.49	813,344 shs	1.09 million shs
LXRX Lexicon Pharmaceuticals	$2.34 -0.4%	$2.24	$1.03 ▼ $2.68	$1.05B	1.08	2.91 million shs	2.31 million shs
WVE WAVE Life Sciences	$5.20 -0.8%	$5.88	$5.01 ▼ $21.73	$1.03B	-1.26	2.76 million shs	6.05 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	+8.16%	+18.22%	+10.42%	-18.88%	+13.98%
JBIO Jade Biosciences	+2.59%	+7.06%	+11.57%	+1.97%	+224.83%
LXRX Lexicon Pharmaceuticals	-0.43%	-0.85%	+10.38%	+4.93%	+110.81%
WVE WAVE Life Sciences	-0.76%	-13.62%	-15.17%	-23.19%	-40.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	2.83	Moderate Buy	$7.00	120.13% Upside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.75	117.35% Upside
LXRX Lexicon Pharmaceuticals	2.25	Hold	$4.55	94.44% Upside
WVE WAVE Life Sciences	2.94	Moderate Buy	$22.53	333.26% Upside

Current Analyst Ratings Breakdown

Latest CLLS, JBIO, WVE, and LXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/10/2026	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$45.00 ➝ $47.00
8/10/2026	JBIO Jade Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$74.00 ➝ $77.00
8/4/2026	WVE WAVE Life Sciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00 ➝ $23.00
8/3/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.00
8/3/2026	WVE WAVE Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/31/2026	WVE WAVE Life Sciences	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $22.00
7/31/2026	WVE WAVE Life Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $19.00
7/31/2026	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$15.00 ➝ $12.00
7/23/2026	LXRX Lexicon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$79.59M	4.01	N/A	N/A	$0.41 per share	7.76
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.74 per share	N/A
LXRX Lexicon Pharmaceuticals	$49.80M	20.91	N/A	N/A	$0.39 per share	6.00
WVE WAVE Life Sciences	$42.73M	23.98	N/A	N/A	$2.30 per share	2.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$67.59M	-$0.65	N/A	N/A	N/A	-102.34%	-94.19%	-21.34%	N/A
JBIO Jade Biosciences	-$127.41M	-$1.92	N/A	N/A	N/A	N/A	-56.87%	-52.74%	N/A
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	N/A
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	N/A

Latest CLLS, JBIO, WVE, and LXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	JBIO Jade Biosciences	-$0.66	-$0.76	-$0.10	-$0.76	N/A	N/A
8/6/2026	H1 2026	CLLS Cellectis	-$0.2630	-$0.22	+$0.0430	-$0.22	$11.05 million	$6.90 million
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	1.61	1.37	1.37
JBIO Jade Biosciences	N/A	14.29	14.29
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
JBIO Jade Biosciences	N/A
LXRX Lexicon Pharmaceuticals	74.70%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
JBIO Jade Biosciences	23.06%
LXRX Lexicon Pharmaceuticals	14.00%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	290	100.34 million	83.87 million	Optionable
JBIO Jade Biosciences	20	63.60 million	37.98 million	N/A
LXRX Lexicon Pharmaceuticals	140	444.96 million	382.66 million	Optionable
WVE WAVE Life Sciences	240	197.05 million	149.17 million	Optionable

CLLS, JBIO, WVE, and LXRX Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in Stock

41 minutes ago | insidertrades.com

Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

August 13 at 11:06 PM | marketbeat.com

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock

August 13 at 11:06 PM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares

August 13 at 11:06 PM | marketbeat.com

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

August 13 at 9:05 AM | 247wallst.com

Wave Life Sciences: An Fairly Valued RNA Opportunity

August 12 at 4:34 AM | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Here's What Happened

August 12 at 4:19 AM | marketbeat.com

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11 at 5:57 PM | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

August 11 at 2:59 PM | marketbeat.com

Wave Life Sciences Completes Redomiciliation to Delaware

August 10, 2026 | finance.yahoo.com

WAVE Life Sciences (NASDAQ:WVE) Shares Gap Up - Here's Why

August 10, 2026 | marketbeat.com

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026 | globenewswire.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 10, 2026 | marketbeat.com

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

August 7, 2026 | finance.yahoo.com

WAVE Life Sciences Ltd. $WVE Shares Purchased by Renaissance Technologies LLC

August 7, 2026 | marketbeat.com

Mizuho Has Lowered Expectations for WAVE Life Sciences (NASDAQ:WVE) Stock Price

August 6, 2026 | americanbankingnews.com

HC Wainwright Has Optimistic Outlook of WVE Q3 Earnings

August 6, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB)

August 5, 2026 | theglobeandmail.com

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

August 5, 2026 | globenewswire.com

Mizuho Lowers WAVE Life Sciences (NASDAQ:WVE) Price Target to $23.00

August 4, 2026 | marketbeat.com

Wave Life Sciences to Present at Upcoming Investor Conferences

August 4, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, JBIO, WVE, and LXRX Company Descriptions

Cellectis NASDAQ:CLLS

$3.18 +0.24 (+8.16%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$3.18 0.00 (-0.03%)

As of 04:10 AM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Jade Biosciences NASDAQ:JBIO

$23.81 +0.60 (+2.59%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$23.80 0.00 (-0.02%)

As of 04:00 AM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.34 -0.01 (-0.43%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$2.33 -0.01 (-0.60%)

As of 07:38 AM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

WAVE Life Sciences NASDAQ:WVE

$5.20 -0.04 (-0.76%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$5.22 +0.02 (+0.38%)

As of 08:32 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, JBIO, WVE, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, JBIO, WVE, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, JBIO, WVE, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, JBIO, WVE, and LXRX Company Descriptions

Cellectis NASDAQ:CLLS

Jade Biosciences NASDAQ:JBIO

Lexicon Pharmaceuticals NASDAQ:LXRX

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLLS, JBIO, WVE, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLLS, JBIO, WVE, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLLS, JBIO, WVE, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, JBIO, WVE, and LXRX Company Descriptions

Cellectis NASDAQ:CLLS

Jade Biosciences NASDAQ:JBIO

Lexicon Pharmaceuticals NASDAQ:LXRX

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools